Form 4 for ANAB ANAPTYSBIO, INC
Accepted 2025-07-03 00:00:00 ET · period of report 2025-07-02 · accession 0001415889-25-019242 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-07-03 | 2025-07-02 | ANAB | RENTON HOLLINGS | Dir | M - OptEx | $6.93 | +20.9K | 25.9K | +421% | +$145.0K |
| DM | 2025-07-03 | 2025-07-02 | ANAB | RENTON HOLLINGS | Dir | S - Sale+OE | $23.57 | -20.9K | 18.6K | -53% | -$493.1K |
| D | 2025-07-03 | 2025-07-02 | ANAB | RENTON HOLLINGS | Dir | M - OptEx | $0.00 | -20.9K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-07-02 | M | A | 20,925 | $6.93 | 25,890 | D | — | — | |
| 2 | Common | Common Stock | 2025-07-02 | S | D | 13,675 | $23.82 | 4,965 | D | — | — | (F3) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.56 to $24.015 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2025-07-02 | S | D | 7,250 | $23.09 | 18,640 | D | — | — | (F2) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.425 to $23.395 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Derivative | Common Stock | 2025-07-02 | M | D | 20,925 | $0.00 | 0 | D | $6.93 · — to 2025-07-05 | 20,925 Common Stock | (F5) In addition to the remaining options to purchase 20,925 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 112,051 shares of common stock, which options vest according to their terms. (F4) The stock option grant was issued on July 6, 2015, is fully vested and exercisable until its expiration date of July 5, 2025. |